Entities / Person
Hengrui.
Republic of China person CBDB = 91660
- Reports this week
- 0
- Active events
- 0
- Connections
- 9
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Hengrui Pharma is developing obesity treatments, with Su Zhang leading non-oncology clinical development at the company.Some support1 report
-
Hengrui has formed broad partnerships and licensing deals with Merck & Co., GSK, and Merck KGaA regarding advanced heart disease drugs for hypertrophic cardiomyopathy.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Hengrui this week
News at the entities that move Hengrui mostConnections
The 3 strongest of 9, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Bristol-Myers Squibb Transactional
The relationship is characterized by the announcement and execution of significant business deals concerning drug program development.
-
Su Zhang Structural
Su Zhang holds the role of leading Non-Oncology Clinical Development at Hengrui Pharma.
-
Scott Wasserman Operational
Both individuals are involved in the competitive development of obesity treatments.